Plant Name: Inulanthera calva
Taxonomic Information:
Plant ID: NPO11127
Plant Latin Name: Inulanthera calva
Taxonomy Genus: Inulanthera
Taxonomy Family: Asteraceae
Plant External Links:
NCBI TaxonomyDB:
127985
Plant-of-the-World-Online:
n.a.
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; | |
| ACHE; | |
| TDP1; BLM; HSD17B1; HSD17B2; AOX1; | |
| EGFR; CSNK2A1; | |
| CA12; CA7; CA4; | |
| ESR1; ESR2; | |
| NR1H4; | |
| ESRRB; ESRRA; | |
| TYR; | |
| AHR; | |
| LMNA; NPC1; RAB9A; THPO; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Enzyme_unclassified | AOX1 | Aldehyde oxidase | Q06278 | CHEMBL3257 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Nuclear hormone receptor subfamily 3 group B | ESRRB | Estrogen-related receptor beta | O95718 | CHEMBL3751 |
| Nuclear hormone receptor subfamily 3 group B | ESRRA | Estrogen-related receptor alpha | P11474 | CHEMBL3429 |
| Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0005496; steroid binding | 3.898E-11 | 2.743E-07 | ESR1, ESR2, ESRRA, ESRRB, HSD17B1, NPC1, NR1H4 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 5.158E-11 | 2.743E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C9, CYP2D6 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.751E-10 | 4.767E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2D6 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 8.548E-10 | 1.692E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C9 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 3.141E-09 | 5.261E-06 | AOX1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C9, CYP2D6 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 2.409E-08 | 2.603E-05 | CYP1A1, CYP1A2, CYP1B1, CYP2C9 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 3.155E-08 | 2.987E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C9, CYP2D6 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 6.067E-08 | 4.403E-05 | CYP1A2, CYP2C9, CYP2D6 |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 1.841E-07 | 1.179E-04 | CYP19A1, CYP1A1, CYP2C9, CYP2D6 |
| BP | GO:0009987; cellular process | GO:0030522; intracellular receptor signaling pathway | 2.028E-07 | 1.262E-04 | AHR, ESR1, ESR2, ESRRA, ESRRB, NR1H4 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 6.633E-07 | 3.283E-04 | CYP1A2, CYP2C9, CYP2D6 |
| BP | GO:0008152; metabolic process | GO:0006703; estrogen biosynthetic process | 8.614E-07 | 4.078E-04 | CYP19A1, HSD17B1, HSD17B2 |
| BP | GO:0009987; cellular process | GO:0043401; steroid hormone mediated signaling pathway | 1.333E-06 | 6.082E-04 | ESR1, ESR2, ESRRA, ESRRB, NR1H4 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.368E-06 | 6.082E-04 | CA12, CA4, CA7 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.858E-06 | 7.934E-04 | BLM, CA12, CA4, CA7, ESR1, ESR2, ESRRA, ESRRB, NR1H4 |
| MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 2.176E-06 | 8.942E-04 | ESR1, ESR2 |
| BP | GO:0008152; metabolic process | GO:0006367; transcription initiation from RNA polymerase II promoter | 3.704E-06 | 1.415E-03 | ESR1, ESR2, ESRRA, ESRRB, NR1H4 |
| CC | GO:0016020; membrane | GO:0005789; endoplasmic reticulum membrane | 5.173E-06 | 1.942E-03 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C9, CYP2D6, EGFR, HSD17B2, RAB9A |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 5.281E-06 | 1.948E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 1.151E-05 | 3.978E-03 | BLM, CYP1A1, CYP1B1, EGFR, ESR1, NPC1 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 1.303E-05 | 4.113E-03 | CYP1A1, CYP1A2 |
| MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 1.303E-05 | 4.113E-03 | ESR1, ESR2 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.303E-05 | 4.113E-03 | CYP1A2, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 2.101E-05 | 6.153E-03 | CA12, CA4, CA7 |
| MF | GO:0005488; binding | GO:0003690; double-stranded DNA binding | 2.119E-05 | 6.153E-03 | AHR, EGFR, ESR1, ESR2, ESRRA, ESRRB, NR1H4, TDP1 |
| BP | GO:0050896; response to stimulus | GO:0032355; response to estradiol | 3.393E-05 | 9.122E-03 | CYP1A2, EGFR, ESR1, ESRRA |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 3.402E-10 | 2.518E-08 | HSD17B1, ALOX5, HSD17B2, CYP1A1, CYP1B1, PTGS2, CYP19A1 |
| Unclassified | Unclassified | hsa01100 | Metabolic pathways | 4.128E-10 | 2.518E-08 | MGAM, MAOA, ALOX15, AKR1B1, PTGS2, CYP2C19, CYP3A4, TYR, CYP19A1, CYP2C9, PKM, ALDH2, HSD17B1, ALOX5, TBXAS1, HSD17B2, CYP1A2, ALDH1A1, CYP1A1, AOX1, XDH |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 3.410E-10 | 2.518E-08 | CYP2C9, CHRNA7, CYP1A2, CYP1A1, CYP1B1, CYP3A4, CYP2C19, PTGS2 |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 8.480E-09 | 1.724E-07 | AR, GSK3B, CDK6, FLT3, DAPK1, ABL1, MAPK1, PTGS2, HIF1A, TP53, EGFR, NFKB1 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 1.002E-09 | 4.586E-08 | HSD17B1, CYP1A2, HSD17B2, CYP1A1, CYP1B1, CYP3A4, CYP19A1 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 3.493E-09 | 9.884E-08 | CYP2C9, MAOA, CYP2D6, CYP1A2, AOX1, CYP3A4, CYP2C19 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 4.198E-09 | 9.884E-08 | CYP2C9, CYP2D6, MAOA, ALOX5, ALOX15, MAPK1, CYP2C19, PTGS2 |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 4.321E-09 | 9.884E-08 | ALDH2, MAOA, CYP1A2, CYP1A1, AOX1, CYP1B1 |
| 09150 Organismal Systems | 09154 Digestive system | hsa04976 | Bile secretion | 4.283E-09 | 9.884E-08 | SLCO1B1, CA2, SLCO1B3, NR1H4, CYP3A4, CFTR, ABCG2 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 6.527E-08 | 1.086E-06 | CYP2C9, ALOX5, ALOX15, TBXAS1, CYP2C19, PTGS2 |
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 1.046E-07 | 1.472E-06 | PKM, FLT3, MAPK1, TP53, HIF1A, EGFR |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 8.700E-08 | 1.327E-06 | CYP2C9, CYP1A2, ALDH1A1, CYP1A1, AOX1, CYP3A4 |
| 09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 5.742E-07 | 6.568E-06 | GSK3B, AR, MAPK1, TP53, EGFR, NFKB1 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 1.755E-07 | 2.294E-06 | CYP2C9, CYP2D6, CYP1A2, CYP1A1, CYP1B1, CYP3A4 |
| 09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 7.118E-07 | 7.662E-06 | ABCC1, CDK6, ABL1, CYP1B1, MAPK1, PTGS2, TP53, EGFR, NFKB1 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 4.361E-08 | 7.980E-07 | CYP2C9, CYP1A2, ALOX15, CYP3A4, CYP2C19 |
| 09160 Human Diseases | 09161 Cancers | hsa05212 | Pancreatic cancer | 2.978E-06 | 3.027E-05 | CDK6, MAPK1, TP53, EGFR, NFKB1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04917 | Prolactin signaling pathway | 4.589E-06 | 4.420E-05 | GSK3B, MAPK1, ESR1, NFKB1, ESR2 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05162 | Measles | 6.854E-06 | 5.972E-05 | GSK3B, CDK6, CSNK2A1, RAB9A, TP53, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05220 | Chronic myeloid leukemia | 4.914E-06 | 4.496E-05 | CDK6, ABL1, MAPK1, TP53, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05203 | Viral carcinogenesis | 6.952E-05 | 4.626E-04 | CDK6, PKM, SYK, MAPK1, TP53, NFKB1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04919 | Thyroid hormone signaling pathway | 5.087E-05 | 3.724E-04 | GSK3B, MAPK1, TP53, ESR1, HIF1A |
| 09150 Organismal Systems | 09156 Nervous system | hsa04722 | Neurotrophin signaling pathway | 5.512E-05 | 3.880E-04 | GSK3B, ABL1, MAPK1, TP53, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05223 | Non-small cell lung cancer | 3.929E-05 | 2.996E-04 | CDK6, MAPK1, TP53, EGFR |
| 09160 Human Diseases | 09161 Cancers | hsa05213 | Endometrial cancer | 2.926E-05 | 2.328E-04 | GSK3B, MAPK1, TP53, EGFR |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 1.565E-04 | 8.677E-04 | GSK3B, CDK6, SYK, MAPK1, TP53, EGFR, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05160 | Hepatitis C | 8.985E-05 | 5.670E-04 | GSK3B, MAPK1, TP53, EGFR, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05214 | Glioma | 7.078E-05 | 4.626E-04 | CDK6, MAPK1, TP53, EGFR |
| 09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 1.126E-05 | 9.363E-05 | DAPK1, MAPK1, TP53, EGFR |
| 09150 Organismal Systems | 09151 Immune system | hsa04662 | B cell receptor signaling pathway | 1.115E-04 | 6.471E-04 | GSK3B, SYK, MAPK1, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 1.000E-04 | 6.102E-04 | CDK6, MAPK1, TP53, EGFR |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04012 | ErbB signaling pathway | 2.200E-04 | 1.150E-03 | GSK3B, ABL1, MAPK1, EGFR |
| 09160 Human Diseases | 09161 Cancers | hsa05222 | Small cell lung cancer | 2.104E-04 | 1.132E-03 | CDK6, PTGS2, TP53, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05169 | Epstein-Barr virus infection | 6.224E-04 | 2.773E-03 | GSK3B, SYK, CSNK2A1, TP53, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 6.364E-04 | 2.773E-03 | MAPK1, TP53, HIF1A, ESR1, EGFR |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 3.608E-04 | 1.738E-03 | MAPK1, ESR1, EGFR, ESR2 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 4.195E-04 | 1.968E-03 | MAPK1, HIF1A, EGFR, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04064 | NF-kappa B signaling pathway | 2.842E-04 | 1.406E-03 | SYK, CSNK2A1, PTGS2, NFKB1 |
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04210 | Apoptosis | 1.324E-03 | 5.155E-03 | LMNA, MAPK1, TP53, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04071 | Sphingolipid signaling pathway | 7.464E-04 | 3.177E-03 | ABCC1, MAPK1, TP53, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04010 | MAPK signaling pathway | 1.756E-03 | 6.427E-03 | MAPK1, MAPT, TP53, EGFR, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05161 | Hepatitis B | 1.545E-03 | 5.770E-03 | CDK6, MAPK1, TP53, NFKB1 |
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04110 | Cell cycle | 8.438E-04 | 3.509E-03 | GSK3B, CDK6, ABL1, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 9.645E-04 | 3.923E-03 | FLT3, MAPK1, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05210 | Colorectal cancer | 1.232E-03 | 4.900E-03 | GSK3B, MAPK1, TP53 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05140 | Leishmaniasis | 1.972E-03 | 7.077E-03 | MAPK1, PTGS2, NFKB1 |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04520 | Adherens junction | 2.051E-03 | 7.217E-03 | CSNK2A1, MAPK1, EGFR |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05131 | Shigellosis | 1.412E-03 | 5.384E-03 | ABL1, MAPK1, NFKB1 |
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 2.813E-07 | 3.432E-06 | CA12, CA2, CA4, CA7 |
| 09130 Environmental Information Processing | 09131 Membrane transport | hsa02010 | ABC transporters | 4.506E-04 | 2.061E-03 | ABCC1, CFTR, ABCG2 |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00350 | Tyrosine metabolism | 2.276E-04 | 1.157E-03 | MAOA, AOX1, TYR |
| 09150 Organismal Systems | 09155 Excretory system | hsa04964 | Proximal tubule bicarbonate reclamation | 2.752E-03 | 9.502E-03 | CA2, CA4 |
| 09100 Metabolism | 09110 Biosynthesis of other secondary metabolites | hsa00232 | Caffeine metabolism | 1.132E-04 | 6.471E-04 | CYP1A2, XDH |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
| C00-D49: Neoplasms | Colon cancer | C50 | EGFR; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | EGFR; |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | ESR1; |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1; |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9; |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | EGFR; |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1; |
| NA: NA | Postmenopausal disorder | NA | ESR1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR; |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1; |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1; |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6; |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1; |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1; |
| C00-D49: Neoplasms | Multiple myeloma | C90 | AHR; |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; |
| C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR; |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1; |
| C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR; |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | RAB9A; |
| C00-D49: Neoplasms | Bladder cancer | C67 | EGFR; CYP19A1; |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | ESR1; ESRRA; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ESRRA; |
| NA: NA | HIV infections | NA | AHR; |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ESRRA; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | ESRRA; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | EGFR; |
| C00-D49: Neoplasms | Breast cancer | C50 | ESR1; EGFR; CYP19A1; |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1; EGFR; |
| H00-H59: Diseases of the eye and adnexa | Choroidal neovascularisation | H35 | ESRRA; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | EGFR; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | ESR1; |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | EGFR; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ESR1; ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; |
| C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; ACHE; |
| C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR; |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | EGFR; |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1; |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1; |
| C00-D49: Neoplasms | Prostate cancer | C61 | ESR1; EGFR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | EGFR; |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | EGFR; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1; |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1; |
| C00-D49: Neoplasms | Gastric cancer | C16 | EGFR; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | EGFR; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | EGFR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | ESRRA; |
| C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | ESRRA; TYR; |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
| NA: NA | Upper abdominal bloating | NA | ACHE; |
| C00-D49: Neoplasms | Urethral cancer | NA | EGFR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ESRRA; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | ESRRA; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
| A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | EGFR; |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | ESRRA; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | TYR; |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | ESRRA; EGFR; |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | ESR1; |
| NA: NA | Menopausal disorder | NA | ESR1; |
| C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR; |
| C00-D49: Neoplasms | Melanoma | C43 | EGFR; TYR; |
| C00-D49: Neoplasms | Cancer | C00-C96 | ESR1; CSNK2A1; ACHE; EGFR; |
| NA: NA | Gonorrheal vaginitis | NA | ESR1; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | EGFR; |
| C00-D49: Neoplasms | Glioma | C71 | EGFR; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | ESRRA; |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6; |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | EGFR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
| C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | EGFR; |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1; |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
